Cargando…

Research progress of biomarkers in the prediction of anti-PD-1/PD-L1 immunotherapeutic efficiency in lung cancer

Currently, anti-PD-1/PD-L1 immunotherapy using immune checkpoint inhibitors is widely used in the treatment of multiple cancer types including lung cancer, which is a leading cause of cancer death in the world. However, only a limited proportion of lung cancer patients will benefit from anti-PD-1/PD...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Luyao, Yang, Zongxing, Guo, Fucheng, Chen, Yurong, Wei, Jiarui, Dai, Xiangpeng, Zhang, Xiaoling
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10351040/
https://www.ncbi.nlm.nih.gov/pubmed/37465684
http://dx.doi.org/10.3389/fimmu.2023.1227797
_version_ 1785074255626502144
author Wang, Luyao
Yang, Zongxing
Guo, Fucheng
Chen, Yurong
Wei, Jiarui
Dai, Xiangpeng
Zhang, Xiaoling
author_facet Wang, Luyao
Yang, Zongxing
Guo, Fucheng
Chen, Yurong
Wei, Jiarui
Dai, Xiangpeng
Zhang, Xiaoling
author_sort Wang, Luyao
collection PubMed
description Currently, anti-PD-1/PD-L1 immunotherapy using immune checkpoint inhibitors is widely used in the treatment of multiple cancer types including lung cancer, which is a leading cause of cancer death in the world. However, only a limited proportion of lung cancer patients will benefit from anti-PD-1/PD-L1 therapy. Therefore, it is of importance to predict the response to immunotherapy for the precision treatment of patients. Although the expression of PD-L1 and tumor mutation burden (TMB) are commonly used to predict the clinical response of anti-PD-1/PD-L1 therapy, other factors such as tumor-specific genes, dMMR/MSI, and gut microbiome are also promising predictors for immunotherapy in lung cancer. Furthermore, invasive peripheral blood biomarkers including blood DNA-related biomarkers (e.g., ctDNA and bTMB), blood cell-related biomarkers (e.g., immune cells and TCR), and other blood-related biomarkers (e.g., soluble PD-L1 and cytokines) were utilized to predict the immunotherapeutic response. In this review, the current achievements of anti-PD-1/PD-L1 therapy and the potential biomarkers for the prediction of anti-PD-1/PD-L1 immunotherapy in lung cancer treatment were summarized and discussed.
format Online
Article
Text
id pubmed-10351040
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-103510402023-07-18 Research progress of biomarkers in the prediction of anti-PD-1/PD-L1 immunotherapeutic efficiency in lung cancer Wang, Luyao Yang, Zongxing Guo, Fucheng Chen, Yurong Wei, Jiarui Dai, Xiangpeng Zhang, Xiaoling Front Immunol Immunology Currently, anti-PD-1/PD-L1 immunotherapy using immune checkpoint inhibitors is widely used in the treatment of multiple cancer types including lung cancer, which is a leading cause of cancer death in the world. However, only a limited proportion of lung cancer patients will benefit from anti-PD-1/PD-L1 therapy. Therefore, it is of importance to predict the response to immunotherapy for the precision treatment of patients. Although the expression of PD-L1 and tumor mutation burden (TMB) are commonly used to predict the clinical response of anti-PD-1/PD-L1 therapy, other factors such as tumor-specific genes, dMMR/MSI, and gut microbiome are also promising predictors for immunotherapy in lung cancer. Furthermore, invasive peripheral blood biomarkers including blood DNA-related biomarkers (e.g., ctDNA and bTMB), blood cell-related biomarkers (e.g., immune cells and TCR), and other blood-related biomarkers (e.g., soluble PD-L1 and cytokines) were utilized to predict the immunotherapeutic response. In this review, the current achievements of anti-PD-1/PD-L1 therapy and the potential biomarkers for the prediction of anti-PD-1/PD-L1 immunotherapy in lung cancer treatment were summarized and discussed. Frontiers Media S.A. 2023-07-03 /pmc/articles/PMC10351040/ /pubmed/37465684 http://dx.doi.org/10.3389/fimmu.2023.1227797 Text en Copyright © 2023 Wang, Yang, Guo, Chen, Wei, Dai and Zhang https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Immunology
Wang, Luyao
Yang, Zongxing
Guo, Fucheng
Chen, Yurong
Wei, Jiarui
Dai, Xiangpeng
Zhang, Xiaoling
Research progress of biomarkers in the prediction of anti-PD-1/PD-L1 immunotherapeutic efficiency in lung cancer
title Research progress of biomarkers in the prediction of anti-PD-1/PD-L1 immunotherapeutic efficiency in lung cancer
title_full Research progress of biomarkers in the prediction of anti-PD-1/PD-L1 immunotherapeutic efficiency in lung cancer
title_fullStr Research progress of biomarkers in the prediction of anti-PD-1/PD-L1 immunotherapeutic efficiency in lung cancer
title_full_unstemmed Research progress of biomarkers in the prediction of anti-PD-1/PD-L1 immunotherapeutic efficiency in lung cancer
title_short Research progress of biomarkers in the prediction of anti-PD-1/PD-L1 immunotherapeutic efficiency in lung cancer
title_sort research progress of biomarkers in the prediction of anti-pd-1/pd-l1 immunotherapeutic efficiency in lung cancer
topic Immunology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10351040/
https://www.ncbi.nlm.nih.gov/pubmed/37465684
http://dx.doi.org/10.3389/fimmu.2023.1227797
work_keys_str_mv AT wangluyao researchprogressofbiomarkersinthepredictionofantipd1pdl1immunotherapeuticefficiencyinlungcancer
AT yangzongxing researchprogressofbiomarkersinthepredictionofantipd1pdl1immunotherapeuticefficiencyinlungcancer
AT guofucheng researchprogressofbiomarkersinthepredictionofantipd1pdl1immunotherapeuticefficiencyinlungcancer
AT chenyurong researchprogressofbiomarkersinthepredictionofantipd1pdl1immunotherapeuticefficiencyinlungcancer
AT weijiarui researchprogressofbiomarkersinthepredictionofantipd1pdl1immunotherapeuticefficiencyinlungcancer
AT daixiangpeng researchprogressofbiomarkersinthepredictionofantipd1pdl1immunotherapeuticefficiencyinlungcancer
AT zhangxiaoling researchprogressofbiomarkersinthepredictionofantipd1pdl1immunotherapeuticefficiencyinlungcancer